359 results on '"Worel, N."'
Search Results
2. Prophylactic Use of Extracorporeal Photopheresis (ecp) - A Prospective Randomized Single Center Trial
3. JACIE accreditation for blood and marrow transplantation: past, present and future directions of an international model for healthcare quality improvement
4. Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use
5. Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources
6. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party
7. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
8. FILGRASTIM- VERSUS CHEMOTHERAPY-BASED AUTOLOGOUS HEMATOPOIETIC STEM CELL MOBILIZATION IN THE SETTING OF PREEMPTIVE (‘JUST-IN-TIME’) PLERIXAFOR: PRELIMINARY DATA OF A NON-INTERVENTIONAL STUDY: 008
9. Allogeneic hematopoietic stem cell donation—standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT)
10. SAFETY AND EFFICACY OF TISAGENLECLEUCEL PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: UPDATED ANALYSIS OF THE PHASE 1B PORTIA STUDY
11. EPSTEIN‐BARR VIRUS‐DRIVEN DISEASES: A MULTINATIONAL, MULTICOHORT, OPEN‐LABEL PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF TABELECLEUCEL USING AN ADAPTIVE STUDY DESIGN
12. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization
13. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study
14. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA
15. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF
16. Regeneration, health status and quality of life after rhG-CSF-stimulated stem cell collection in healthy donors: a cross-sectional study
17. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases
18. (114) Prophylactic Use of Extracorporeal Photopheresis (ecp) - A Prospective Randomized Single Center Trial
19. 29P ALLELE study: A multicenter, open label, phase III study of tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after failure of rituximab or rituximab and chemotherapy
20. Prolonged red cell aplasia after major ABO-incompatible allogeneic hematopoietic stem cell transplantation: removal of persisting isohemagglutinins with Ig-Therasorb® immunoadsorption
21. Long-term outcome and quality of life of patients who are alive and in complete remission more than two years after allogeneic and syngeneic stem cell transplantation
22. Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma
23. Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants
24. Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF
25. Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversion inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26)
26. Extracorporeal Photopheresis in Patients with High Bleeding Risks: SP154
27. Plasma Exchange Therapy Using AmicusTM (Fenwal) Is a Safe Treatment For Patients and a Simple Procedure For the Staff: SP146
28. Administration of Prednisolone intravenously or Dexamethason orally in random donors reveals equal results in granulocyte collection: a single centre experience
29. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia
30. Hematopoietic donor chimerism and graft-versus-myeloma effect in relapse of multiple myeloma after allogeneic bone marrow transplantation
31. Quality controls of cryopreserved haematopoietic progenitor cells (peripheral blood, cord blood, bone marrow)
32. Haematopoietic stem cell mobilization with plerixafor in patients with non-haematological diseases: P1202
33. Autologous haematopoietic stem cell mobilization with plerixafor and G-CSF: impact of apheresis volume. Data from the Plerixafor European Compassionate Use Study: P1083
34. The role of the CXCR4 antagonist Plerixafor® in elderly patients failing autologous stem cell mobilization. Data from the Plerixafor Compassionate Use Study. On behalf of the European Consortium for Stem Cell Mobilization (ECOSM): P1073
35. Autologous haematopoietic stem cell mobilization with plerixafor and G-CSF: impact of overweight and obesity: P1077
36. Plerixafor for stem cell mobilization in Hodgkin, non- Hodgkin, and multiple myeloma patients: a subgroup analysis from the European Compassionate Use Program: P1075
37. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF
38. Extracorporeal Photopheresis Immediately after Heart Transplantation in High Risk Patients
39. Graft-versus-host disease following second syngeneic stem cell transplantation for relapsed chronic myeloid leukemia
40. Red blood units collected from bone marrow harvests after mononuclear cell selection qualify for autologous use
41. Stem cell harvesting and transplantation
42. STEM CELL HARVESTING AND TRANSPLANTATION: AC07
43. Mechanisms underlying acquired von Willebrand syndrome associated with an IgM paraprotein
44. Improved mobilisation of peripheral blood CD34+ cells by AMD3100 plus granulocyte-colony-stimulating factor in hard to mobilise patients: R1223
45. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation
46. Successful unrelated haematopoietic stem cell transplantation in a severely alloimmunised patient with acute T-lymphoblastic leukaemia
47. Apheresis products of the Amicus™ and the AS.TEC 204® cell separators are comparable with regard to dendritic cells derived from the mononuclear cell collection
48. CURRENT STATUS OF PREPARATIVE GRANULOCYTE APHERESIS: DONOR SELECTION, INDICATIONS AND TECHNIQUES: P-442
49. Fibrin sealant produced by the CryoSeal® FS System: product chemistry, material properties and possible preparation in the autologous preoperative setting
50. Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.